Merck Sharp & Dohme (6MK) – tečaj delnic in novice

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue. The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products. The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000. In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck". Wikipedia

Vizitka: Merck Sharp & Dohme

Generalni direktorRobert M Davis

Št. zaposlenih74 tis.

Ustanovljeno1. jan. 1891

Sedež-

Sektor-

Spletno mestomerck.com

Vse vrednosti v valuti USD	sep. 2025	dec. 2025	mar. 2026	jun. 2026
Prihodek	17,28 mrd.	16,40 mrd.	16,29 mrd.	16,61 mrd.
Strošek prodanega blaga	3,74 mrd.	4,30 mrd.	3,88 mrd.	4,13 mrd.
Stroški materiala in storitev	3,74 mrd.	4,30 mrd.	3,88 mrd.	4,13 mrd.
Stroški raziskav in razvoja	4,00 mrd.	4,00 mrd.	3,56 mrd.	9,74 mrd.
Skupni stroški raziskav in razvoja	-	-	-	-
Stroški prodaje, splošni in administrativni stroški	2,48 mrd.	2,73 mrd.	2,57 mrd.	2,78 mrd.
Operativni strošek	6,48 mrd.	6,73 mrd.	6,12 mrd.	12,52 mrd.
Skupni operativni stroški	10,23 mrd.	11,02 mrd.	10,00 mrd.	16,65 mrd.
Prihodek iz poslovanja	7,05 mrd.	5,38 mrd.	6,29 mrd.	−40,00 mio.
Drug prihodek, ki ne izhaja iz poslovanja	-	41,00 mio.	42,00 mio.	59,00 mio.
Zaslužek pred obdavčitvijo z vključenimi izrednimi postavkami	6,74 mrd.	3,42 mrd.	−3,53 mrd.	−683,00 mio.
Zaslužek pred obdavčitvijo brez izrednih postavk	6,76 mrd.	4,98 mrd.	5,85 mrd.	−508,00 mio.
Odhodek iz obdavčitve dobička	958,00 mio.	458,00 mio.	709,00 mio.	654,00 mio.
Dejanska davčna stopnja	14,20 %	13,39 %	−20,06 %	−95,75 %
Drugi operativni stroški	-	-	-	-
Čisti prihodek	5,78 mrd.	2,96 mrd.	−4,24 mrd.	−1,34 mrd.
Neto stopnja dobička	33,49 %	18,07 %	−26,03 %	−8,04 %
Čisti dobiček na delnico	2,58	2,04	−1,28	−0,13
Prihodki iz obresti in naložb	96,00 mio.	69,00 mio.	35,00 mio.	35,00 mio.
Obrestni odhodki	−327,00 mio.	−411,00 mio.	−479,00 mio.	−525,00 mio.
Neto obrestni odhodki	−231,00 mio.	−342,00 mio.	−444,00 mio.	−490,00 mio.
Stroški amortizacije	-	-	-	-
EBITDA	8,15 mrd.	6,79 mrd.	7,69 mrd.	1,43 mrd.
Dobiček ali izguba pri prodaji sredstev	-	-	-	-

Vprašajte kar koli